Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
The study evaluated the Tome Foundational Treatment.
Dermata Therapeutics, Inc. (Nasdaq: DRMA) announced positive topline results from a cosmetic study evaluating its Tome Foundational Treatment.
The study assessed the efficacy and safety of the Tome Foundational Treatment in participants. Dermata Therapeutics reported that the treatment met its primary endpoint, demonstrating statistically significant improvement in skin appearance.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.